NEWS & EVENTS
59th ASH Annual Meeting
December 9 - 12, 2017
Atlanta, GA
Description

NHLBI-Supported Sessions at 59th ASH Annual Meeting

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health will participate in the 59th American Society of Hematology (ASH) Annual Meeting. NHLBI-supported research will be presented at more than 40 sessions. See the schedule below for a snapshot of the NHLBI’s sessions at 59th ASH Annual Meeting.

(NOTE: Schedule is subject to change. Please consult the official ASH schedule.)

Agenda

8:00 a.m.
-
Abstract 68
Reduction in Bone Marrow Insulin-like Growth Factor-1 Levels Enhances Long-Term Hematopoietic Stem Cell Engraftment Following Bone Marrow Transplantation

Location: Building B, Level 3, B302-B303

Presenter: Timothy S. Olson, M.D., Ph.D., The Children’s Hospital of Philadelphia

8:15 a.m.
-
Abstract 75
Increased TLR7 Signaling of BCR-Activated B Cells in Chronic Graft-Versus Host Disease (cGVHD)

Location: Level 3, B308- B309

Presenter: Amy N. Suthers, Ph.D., Department of Medicine, Division of Hematological Malignancies and Cellular Therapy, Duke University Medical Center

9:30 a.m.
-
Special Scientific Symposia
Clonal Hematopoiesis Influences Cardiovascular Risk

Location: Building C, Level 3, Georgia BR 1-3

Presenter: Benjamin Ebert M.D., Ph.D., Division of Hematology, Brigham and Women’s Hospital

10:15 a.m.
-
Abstract 106
Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms

Location: Building C, Level 2, C202-C204

Presenter: Vera Adema, Ph.D., Translational Hematology and Oncology, Cleveland Clinic

12:30 p.m.
-
Abstract 135
The Age of the Hematopoietic Microenvironment Specifies Lineage Commitment in MLL-Rearranged Leukemia

Location: Building B, Level 3, B302- B303

Presenter: Grant Rowe, M.D., Ph.D., Boston Children’s Hospital

3:00 p.m.
-
Abstract 179
FVIII Proteins with a Modified Immunodominant T-Cell Epitope Exhibit Reduced Immunogenicity and Normal Procoagulant Activity

Location: Building B, Level 2, B207-B208

Presenter: Kathleen P. Pratt, Ph.D., Department of Medicine, Uniformed Services University of the Health Sciences

4:15 p.m.
-
Abstract 236
The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

Location: Building B, Level 2, B207-B208

Presenter: Michael Wallisch, Ph.D., Department of Biomedical Engineering, Oregon Health & Science University

5:30 p.m.
-
Abstract 990
Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease

Location: Building A, Level 1, Hall A2

Presenter: John F. Tisdale, M.D., NHLBI

5:30 p.m.
-
Abstract 966
Bone Marrow Characterization in Sickle Cell Disease: Inflammation and Stress Erythropoiesis Lead to Suboptimal CD34 Recovery Compared to Normal Volunteer Bone Marrow

Location: Building A, Level 1, Hall A2

Presenter: Alexis Leonard, M.D., Children’s National Health System (NHS),and Molecular and Clinical Hematology Branch (MCHB), NHLBI/NIDDK

5:30 p.m.
-
Abstract 970
Pain and Opioid Use after Reversal of Sickle Cell Disease Following Hematopoietic Stem Cell Transplant

Location: Building A, Level 1, Hall A2

Presenter: Deepika S. Darbari, M.D., George Washington University School of Medicine, Children’s National Medical Center, NHLBI

5:30 p.m.
-
Abstract 1202
Common Fetal Hemoglobin Variants Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs

Location: Building A, Level 1, Hall A2

Presenter: Norris E. Igbineweka, Magnetic Resonance Cholangiopancreatography (MRCP), NHS, NHLBI

7:30 a.m.
-
Abstract 283
Fetal Hemoglobin (HbF) Silencer BCL11A Acts through a Novel DNA-Motif in the Gamma-Globin Promoters, Simplifying the Model for Hemoglobin Switching

Location: Building B, Level 2, B213-B214

Presenter: Nan Liu, Ph.D., Cancer and Blood Disorders Center, Dana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School

9:45 a.m.
-
Abstract 362
Lettuce Plants Expressing High Levels of Factor VIII Antigen in the Chloroplast for Oral Tolerance in Hemophilia A

Location: Building B, Level 2, B207-B208

Presenter: Roland W. Herzog, Ph.D., University of Florida

10:30 a.m.
-
Abstract 383
Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform

Time & Location: , Building C, Level 2, C208-C210

Presenter: Sakiko Suzuki, M.D., Division of Hematology–Oncology, University of Massachusetts Medical School

12:30 p.m.
-
ASH-EHA Joint Symposium
North American Symposium

Location: Building C, Level 1, Hall C2-C3

Presenter: Benjamin Ebert M.D., Ph.D., Division of Hematology, Brigham and Women’s Hospital

2:00 p.m.
-
Abstract 3
Customized Induced Pluripotent Stem Cell-Derived Red Cell Reagents

Location: Building C, Level 1, Hall C2-C3

Presenter: Stella T. Chou, M.D., Division of Hematology, The Children’s Hospital of Philadelphia

4:30 p.m.
-
Abstract 439
Critical Role of Protein Arginine Deiminase 4 in Mast Cell Extracellular Trap Formation Leading to Neuropathic Pain in Sickle Mice

Location: Building B, Level 3, B312-B314

Presenter: Huy Tran, Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota

4:45 p.m.
-
Abstract 440
Uncoupling Sickle Hematopoiesis Induced Angiotensin Receptor Signaling in Sickle Nephropathy

Time & Location: , Building B, Level 3, Hall B312-B314

Presenter: Parul Rai, M.D., Cincinnati Children’s Hospital Medical Center

5:30 p.m.
-
Abstract 443
Vitamin D Repletion Mitigates Oxidative Stress Induced Pulmonary Artery Remodeling in Sickle Cell Disease

Location: Building B, Level 3, B312-B314

Presenter: Julia Brittain, Ph.D., Vascular Biology Center, Augusta University/MCG

5:30 p.m.
-
Abstract 527
Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

Location: Building C, Level 1, C101 Auditorium

Presenter: Julie Kanter, M.D., Lifespan Comprehensive Sickle Cell Center, Medical University of South Carolina

5:45 p.m.
-
Abstract 516
Day 100 Levels of Blood Immune Cells Are Prognostic Biomarkers for Allogeneic Hematopoietic Stem Cell Transplant Outcomes: Results from BMT CTN 0201

Location: Building B, Level 2, B211-B212

Presenter: Shanelle M. Fernando, Winship Cancer Institute, Emory University

6:00 p.m.
-
Abstract 3338
Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors

Location: Building A, Level 1, Hall A2

Presenter: Naoya Uchida, M.D., Ph.D., MCHB, NHLBI/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

6:00 p.m.
-
Abstract 2248
Ventilation-Perfusion Scan Is Superior to CT Pulmonary Angiography in Detection of Chronic Thromboembolic Pulmonary Hypertension in SCD Adults

Location: Building A, Level 1, Hall A2

Presenter: Norris E. Igbineweka, MRCP, NHS, NHLBI

6:00 p.m.
-
Abstract 2234
The NLRP3 Inflammasome in Platelets Is Upregulated in Sickle Cell Disease and Promotes Platelet Aggregation and in Vitro Thrombosis

Location: Building A, Level 1, Hall A2

Presenter: Sebastian Vogel, M.D., Ph.D., NHLBI

7:15 a.m.
-
Abstract 548
Development of a Pure Small Molecule αVβ3 Antagonist

Location: Building B, Level 2, B216-B217

Presenter: Barry S. Coller, M.D., llen and Frances Adler Laboratory of Blood and Vascular Biology, Lab of Blood and Vascular Biology, The Rockefeller University

7:45 a.m.
-
Abstract 556
Rebound Hypercoagulability Following a Conventional Course of Anticoagulation and the Risk of Recurrent Venous Thromboembolism in Young Patients: First Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Location: Building B, Level 2, B207-B208

Presenter: Marisol Betensky, M.D., M.P.H., Johns Hopkins All Children’s Hospital

7:45 a.m.
-
Abstract 598
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Location: Building B, Level 3, B312-B314

Presenter: Mary Eapen, M.S., Medical College of Wisconsin

8:15 a.m.
-
Abstract 606
Aberrant Clonal Hematopoiesis of the Erythroid and Myeloid Lineages in a Lentivirally Barcoded Rhesus Macaque

Location: Building C, Level 1, C101 Auditorium

Presenter: Diego A. Espinoza, NHLBI

3:00 p.m.
-
Abstract 686
HMOX1 and Acute Kidney Injury in Sickle Cell Anemia

Location: Building B, Level 3, B308-B309

Presenter: Santosh L. Saraf, M.D., University of Illinois at Chicago

5:00 p.m.
-
Abstract 765
Anemic Conditions Acceptable in Restrictive Transfusion Practice Induce Gut Inflammation and Injury in an Animal Model of Preterm Infants

Location: Building C, Level 2, C208-C210

Presenter: Connie Arthur, Ph.D., Department of Laboratory Medicine and Pathology, Emory University

5:30 p.m.
-
Abstract 785
Splicesome Mutant MDS and AML Cells Activate Innate Immune Signaling by Regulating the Expression of Therapeutically Targetable IRAK4 Isoforms

Location: Building C, Level 1, C108-C109

Presenter: Molly A. Smith, Ph.D., Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center; Department of Cancer Biology, University of Cincinnati

5:45 p.m.
-
Abstract 774
Comparison of Fetal and Adult Erythroid Chromosomal Architectures Identifies a Novel Fetal Hemoglobin Regulatory Region

Location: Building B, Level 2, B213-B214

Presenter: Peng Huang, Ph.D., Children’s Hospital of Philadelphia

5:45 p.m.
-
Abstract 870
Impact of Sickle Cell Therapies on Growth Patterns

Location: Building C, Level 2, C211-C213

Presenter: Varsha Kulkarni, University of Alabama at Birmingham

6:00 p.m.
-
Abstract 3556
Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Cognition in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b paediatric cohort)

Location: Building A, Level 1, Hall A2

Presenter: April E. Slee, Combined Clinical Trials Unit, University College London

6:00 p.m.
-
Abstract 3537
Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort)

Location: Building A, Level 1, Hall A2

Presenter: Baba Inusa, M.D., MRCP, Paediatric Haematology, Guy’s and St Thomas’ NHS Trust; Becket House, Evelina Children’s Hospital

6:00 p.m.
-
Abstract 3757
Improved ES Cell-Derived Erythroid Cell Generation with Robust b-Globin Production through ES-Sacs

Location: Building A, Level 1, Hall A2

Presenter: Juan Jesus J. Haro Mora, Ph.D., MCHB, NHLBI/NIDDK

6:00 p.m.
-
Abstract 4617
Fetal Hemoglobin Induction with Forced Chromatin Looping in Gene-Modified Erythroid Cells Differentiated from Rhesus Hematopoietic Progenitor Cells

Location: Building A, Level 1, Hall A2

Presenter: Selami Demirci, Ph.D., MCHB, NHLBI/NIDDK

7:15 p.m.
-
Abstract 875
The Activated TGFβ Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q

Location: Building B, Level 3, B302-B303

Presenter: Melisa Ruiz-Gutierrez, M.D., Ph.D., Cancer and Blood Disorders Center, Dana-Farber/Boston Children’s Hospital